Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) — The “Sickle Cell Anemia Testing & Screening Market – Global Forecast 2025-2032” has been added to ResearchAndMarkets.com’s offering.
This report equips senior decision-makers with actionable intelligence and strategic insights, bolstering their planning and investment efforts in the burgeoning sickle cell anemia testing sector.
From 2024 to 2025, the Sickle Cell Anemia Testing & Screening Market grew from USD 1.07 billion to USD 1.21 billion, showcasing a robust compound annual growth rate of 13.90%. This market is forecasted to soar to USD 3.03 billion by 2032, fueled by government and non-profit initiatives for early detection and continuous diagnostic technology advancements. These advances ensure healthcare organizations can offer precise and efficient testing services, meeting the increasing global demand.
The sickle cell anemia testing and screening market is undergoing significant changes driven by advances in diagnostics, regulatory developments, and global health initiatives. Understanding these dynamics is crucial for senior decision-makers aiming to adapt their strategies effectively in this vital healthcare arena.
Why This Report Matters
- Guides senior executives in strategy benchmarking and distribution optimization in response to global trends.
- Assists risk management teams in navigating regulatory updates and tariff changes in the sickle cell anemia testing ecosystem.
Key Takeaways from This Report
- Technological advancements in diagnostics are expanding healthcare access, catering to diverse patient demographics.
- Digital health integration facilitates real-time analytics and remote reporting, enhancing service reach.
- Collaborations among industry leaders and startups expedite technology validation and market entry, promoting innovation.
- Enhanced service offerings, like technical support and training, are building customer loyalty and optimizing investment returns.
- Adapting to regional regulatory disparities is crucial for expanding testing services and meeting varied public health demands.
Market Insights
- Integration of point-of-care neonatal screening tools in decentralized healthcare settings
- Adoption of high-throughput genomic sequencing workflows for early carrier detection in newborns
- Deployment of AI-driven pattern recognition software to differentiate sickle cell trait in screening assays
- Implementation of CRISPR-based molecular assays for precise detection of rare sickle cell gene variants
- Utilization of smartphone-enabled colorimetric assays to expand rural sickle cell screening access
- Expansion of mandatory newborn sickle cell screening programs across sub-Saharan African health systems
- Development of integrated electronic health record systems linking screening results to patient care pathways
- Establishment of telemedicine platforms for remote genetic counseling following positive newborn screening results
- Collaboration between governmental agencies and private laboratories to subsidize community sickle cell screening initiatives
- Introduction of multiplex immunoassay panels to enhance diagnostic throughput and reduce turnaround time in sickle cell testing
Scope & Segmentation of the Sickle Cell Anemia Testing & Screening Market
- Test Types: Includes analyses of high-performance liquid chromatography (HPLC), diverse immunoassays, and molecular testing methods like next-generation sequencing and polymerase chain reaction.
- Product Categories: Covers consumables, laboratory instruments, and services such as technical support and training.
- End Users: Focus on diagnostic laboratories, clinics, and research institutions.
- Sample Types: Evaluation of blood and saliva sampling techniques.
- Distribution Channels: Insights into direct sales, third-party distributors, and online retail strategies.
- Regional Markets: Analysis of regions including the Americas, Europe, Middle East & Africa, and Asia-Pacific, with detailed insights into key countries.
- Key Companies Profiled: Profiles major players such as F. Hoffmann-La Roche Ltd and Abbott Laboratories.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2025 – 2032 |
| Estimated Market Value (USD) in 2025 | $1.21 Billion |
| Forecasted Market Value (USD) by 2032 | $3.03 Billion |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
Companies Featured
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- Becton, Dickinson and Company
- Siemens Healthineers AG
- DiaSorin S.p.A.
- PerkinElmer, Inc.
- Ortho Clinical Diagnostics, Inc.
- QIAGEN N.V.
For more information about this report visit https://www.researchandmarkets.com/r/66vk1i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Sickle Cell Anemia Testing & Screening Market
